RIPK3 and Alzheimer disease: Parallel efforts should also focus on the identification and longitudinal validation of necroptosis-associated biomarkers, such as phosphorylated MLKL or RIPK3, in cerebrospinal fluid and plasma, as studies have detected elevated levels of pMLKL in the CSF of AD patients, which suggests its potential as a diagnostic indicator but also as a predictor of therapeutic response and disease progression.